FDA-Mandated study tracks new DMD drug in 300 patients
NCT ID NCT07127978
Summary
This study will observe 300 patients with Duchenne muscular dystrophy (DMD) who are already taking the approved drug givinostat as part of their regular care. Researchers will track patients for at least two years to monitor the drug's safety, particularly watching for low platelet counts and bleeding risks, while also checking how well it helps maintain muscle function and quality of life. No treatment is provided by the study—it simply collects information from patients' routine doctor visits over five years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ann and Robert H. Lurie Children's Hospital of Chicago
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Massachusetts Chan Medical School
RECRUITINGWorcester, Massachusetts, 01655, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.